LEANDRO CABRAL ZACHARIAS
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Effects of light on retinal pigment epithelial cells, neurosensory retinal cells and Muller cells treated with Brilliant Blue G(2015) MANSOOR, Saffar; SHARMA, Ashish; CACERES-DEL-CARPIO, Javier; ZACHARIAS, Leandro C.; PATIL, A. Jayaprakash; GUPTA, Navin; LIMB, G. Astrid; KENNEY, M. Cristina; KUPPERMANN, Baruch D.Background: The aim of this study is to evaluate the safety profile of Brilliant Blue G (BBG) with and without exposure to light (L) on three different retinal cell lines. Method: ARPE-19, R28 and MIO-M1 cells were treated with BBG: 0.125 mg/mL (0.5x clinical concentration), 0.25 mg/mL (1x) or 0.5 mg/mL (2x) with or without surgical illumination of halogen light exposure for 10 min, 15 min or 30 min. Cells were further cultured after 24 h and then analysed for cell viability, late stages of apoptosis and mitochondrial damage associated with early apoptosis using assays that measure trypan blue dye exclusion, increases in caspase-3/7 activity or changes in mitochondrial membrane potential (Delta Psi m), respectively. Result: All three cell lines that were exposed to BBG in the presence or absence of light exposure for 30 min were found to have cell viability and caspase-3/7 activity levels similar to the untreated cultures. The mitochondrial membrane potential (Delta Psi m) was decreased significantly at the 2x + L dose and 2x dose in all three retinal cell lines compared to their respective untreated control cells. At the lower doses of BBG, with or without exposure to light, the Delta Psi m values were similar to the untreated control cultures. Conclusion: Exposure to BBG dye concentrations that are used clinically (0.125 mg/mL and 0.25 mg/mL) in the presence up to 30 min of surgically equivalent light intensity is safe for retinal cells.
- Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study(2020) SHARMA, Ashish; KUPPERMANN, Baruch D.; BANDELLO, Francesco; LANZETTA, Paolo; ZUR, Dinah; PARK, Sung Wook; YU, Hyeong Gon; SARAVANAN, V. R.; ZACHARIAS, Leandro Cabral; BARREIRA, Alan K.; IGLICKI, Matias; MIASSI, Fernando; VERITTI, Daniele; TSAO, Sean; MAKAM, Deepika; JAIN, Nidhee; LOEWENSTEIN, AnatPurpose To analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations. Methods The medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%). Results Amongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group. Conclusion Latino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.
article Submacular Hemorrhage: How Do You Manage?(2023) ZACHARIAS, Leandro Cabral; NAGPAL, Manish; BAKRI, Sophie- Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study(2020) SHARMA, Ashish; BANDELLO, Francesco; LOEWENSTEIN, Anat; KUPPERMANN, Baruch D.; LANZETTA, Paolo; ZUR, Dinah; HILELY, Assaf; IGLICKI, Matias; VERITTI, Daniele; WANG, Angeline; MIASSI, Fernando; BELLOCQ, David; ZACHARIAS, Leandro Cabral; MAKAM, Deepika; KUMAR, Nilesh; PARACHURI, Nikulaa; BARRIERA, Alan K.; SHARMA, Rohini; FARIDI, Hafeez; MATHIS, Thibaud; KODJIKIAN, LaurentObjective To analyze the role of intravitreal anti-vascular endothelial growth factor (anti-VEGF) or steroid injection for the management of Irvine Gass syndrome. Methods It is an interventional, retrospective, multicenter study. One hundred and thirty-two injections were given in 79 eyes of 72 patients with Irvine Gass syndrome. Patients were treated with at least one intravitreal injection of either anti-VEGF or steroid. Outcomes were measured at 12 months (+/- 1 week). [Ranibizumab (Lucentis; Genentech, South San Francisco, CA) (Razumab; Intas Pharmaceutical Ltd, Ahmedabad, India) Bevacizumab (Avastin; Genentech, South San Francisco, CA) or Aflibercept (Eylea; Regeneron, Tarrytown, NY)] or steroids [Dexamethasone implant (Ozurdex, Allergan Inc, Irvine, CA) or intravitreal triamcinolone)]. Results Intravitreal injections were initiated in (67.6%) of eyes within 14 weeks of diagnosis. Intravitreal dexamethasone implant was used as the initial intravitreal therapy in (73.4%) of eyes. More than fifty percent (54.5%) of the patients were switched from anti-VEGF to Intravitreal dexamethasone implant. Reduction in the mean CMT was 336.7 +/- 191.7 and 160.1 +/- 153.1 microns in eyes treated within four weeks and more than 14 weeks from diagnosis (p = 0.005). Mean ETDRS letter gain was 16.7 +/- 12.9 and 5.2 +/- 9.2 in eyes treated within 4 weeks and more than 14 weeks from diagnosis (p = 0.004). Three eyes injected with intravitreal dexamethasone implant reported an intraocular pressure spike of > 25 mmHg which was controlled with topical medications. No other ocular or systemic adverse events were observed. Conclusion Study results suggest that physicians tend to introduce intravitreal therapy within 14 weeks of diagnosis. The most common therapy at initiation and for the switch is intravitreal dexamethasone implant. Patients treated early (within 4 weeks) respond better in terms of structure and function.